Bharat Parenterals is an injectable-medicines specialist that has spent three decades turning a family trading business into an export-led manufacturing platform - and is now building a second act as a complex-drugs partner for the world’s toughest regulators. The group was born in 1962 when founder Rameshchandra Desai began sourcing pharmaceuticals from third-party manufacturers, moved into production in 1965, and eventually concentrated its operations in Gujarat, where the modern company was incorporated in 1992. The recurring approach is to pick niches with high barriers to entry - sterile injectables, oncology oral liquids, liposomal delivery systems - and then build the regulatory approvals, manufacturing capability and partnership models that turn those barriers into a moat.
Business segments
Four engines at different stages - an export generics cash cow serving over 40 countries, a domestic hospital-brand business that just turned profitable, a US-and-EU complex-generics CDMO with its first approvals in hand, and a pre-revenue emerging-markets injectables platform under construction - each built to address a distinct tier of the global pharmaceutical market.
1. Standalone export manufacturing: the group’s volume engine
A tender-driven injectables factory that sells generic formulations to semi-regulated markets across Africa, Latin America, Southeast Asia and the Middle East, earning revenue one shipment at a time.
- Three dedicated production blocks under one roof - the 300,000 sq.ft. WHO-cGMP facility in Vadodara runs separate General, Beta-Lactam and Cephalosporin lines, so antibiotic and non-antibiotic products never cross-contaminate. Combined capacity covers injectable vials (103 million units), tablets (1.8 billion units), capsules (1.1 billion units), powders and liquids, with utilisation currently at 48% for the general line and roughly 21-24% for the antibiotic blocks - meaning the business can grow 10-15% without new capital expenditure.
- Paid when the tender lands - revenue comes from one-time product sales, mostly through government and institutional tenders in over 40 countries, with an order book at the end of FY26 of INR 171 crores split between domestic tenders, export orders and international tenders. The largest single order ever won - a $27 million supply contract over 18-24 months - was secured during the year.
- Registrations are the entry ticket - the company has over 350 live product filings and submitted 214 dossiers in FY26 alone, receiving 40 new product registrations across Africa, Latin America and Southeast Asia. A representative office in Vietnam was established to strengthen direct presence in the region, and PIC/S and EUGMP inspections are expected during FY27.
- Margins depend on the mix - export-oriented orders typically carry margins in a broad 25-35% range, and the company deliberately exited low-margin volume business in FY26, which contributed to a standalone revenue decline alongside deferred tenders and production-line upgrades to ORABS and EUGMP standards.
2. Innoxel Lifesciences: the complex-generics CDMO for regulated markets
A partner to US and European pharmaceutical companies that need hard-to-make injectables - Innoxel develops the product, gets it approved, and then manufactures it for a share of the profits.
- One of a handful globally - the Vadodara facility is India’s only US FDA-approved Oncology Oral Liquid manufacturing plant and one of only six such facilities worldwide; it is also one of the few SKID-based manufacturing sites in India, built for particulate and extended-release injectables. The plant houses two blocks - general and oncology - with capacity of 0.6 crore vials and 0.3 crore bottles per year, expandable to more than double.
- Two ways to get paid - in the own-products model, Innoxel develops a molecule to a certain stage, out-licenses it to a front-end partner who funds the rest, and then collects milestone payments plus a profit share (typically 20-45%) once the product launches. In the CMO/CDO model, partners pay fees for tech transfer, exhibit batches, scale-up, stability work and eventual commercial manufacturing, with milestone payments at each inflection point.
- The approvals are the moat - the facility received a US FDA Establishment Inspection Report in 2025 with only one minor procedural observation, and was cleared by Belgium’s FAMHP for EUGMP with zero critical and zero major observations, meaning it can now supply both the US and selected European markets commercially. The first commercial CMO supply is expected in Q2 FY27.
- A pipeline of 42 assets and 19 active partners - the portfolio spans liposomal injectables, long-acting injectables, oral-solid-to-oral-liquid conversions and oncology products, with 23 deals signed in FY26 alone (7 out-licensing, 16 CMO/CDO) and partners split across the US, Europe and India. Cumulative licensing revenue since inception has reached INR 72.4 crores, and the subsidiary turned EBITDA-positive for the first time in Q4 FY26.
3. Varenyam Healthcare: branded injectables for Indian hospitals
A domestic institutional business that sells its own branded acute-care and anaesthesia products directly to over 7,500 corporate hospitals - and just became profitable.
- Built around a flagship molecule - the top five brands contribute roughly half of revenue, led by Sugmadex, India’s first Sugammadex 100 mg/ml product and the only one with a three-year shelf life, which crossed INR 10 crores in FY26 sales. The portfolio spans sedatives, reversal agents, local anaesthetics, muscle relaxants and antibiotics, with 45 active brands in total.
- A field force that is getting more productive - 211 medical representatives generated over INR 3.85 lakhs per person per month, a 31% year-on-year improvement, and the plan is to expand to 250-plus representatives in FY27 while launching a second division in gynaecology.
4. Varenyam Biolifesciences: the emerging-markets bet under construction
A pre-revenue injectables platform being built to take complex products - originally developed for the US and Europe - into regulated emerging markets like Brazil, Mexico, South Africa and Australia.
- A facility at the 20% mark - the approved budget is approximately INR 160 crores, with about INR 33 crores spent so far; civil works are 50% complete and equipment procurement is roughly 40%. The timeline points to commissioning by September 2027, first regulatory filing under EUGMP in early FY29, and first commercial supply by the end of FY29.
Group structure and partners
A family-led holding company with three operating subsidiaries, each aimed at a different tier of the global pharmaceutical market - and a promoter group that owns two-thirds of the shares with none pledged.
- Bharat Parenterals Ltd is the listed parent, headquartered in Vadodara and traded on the BSE, with promoter shareholding at 67.17% as of March 2026 and zero pledged shares.
- Innoxel Lifesciences is 55.9% owned by BPL, with the balance held by experienced technocrats who co-founded the venture in 2021; BPL increased its stake from 51% in June 2024 through a cash acquisition of additional equity.
- Varenyam Healthcare became a 100% subsidiary in FY25 when BPL completed a share swap, issuing 351,255 equity shares to acquire the remaining stake in the branded institutional injectables business co-founded by Mr. Bhahim Desai in 2016.
- Varenyam Biolifesciences, incorporated in June 2022, was also brought to 100% ownership via a share swap in FY25, with BPL issuing shares to Varenyam Healthcare as consideration.
- All manufacturing facilities - the standalone plant at Jarod-Samlaya Road, the Innoxel facility and the Varenyam Biolifesciences site under construction - are located in Vadodara, Gujarat.